首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   46095篇
  免费   5148篇
  国内免费   111篇
耳鼻咽喉   640篇
儿科学   1273篇
妇产科学   1270篇
基础医学   7076篇
口腔科学   1080篇
临床医学   6210篇
内科学   8461篇
皮肤病学   608篇
神经病学   3640篇
特种医学   1535篇
外国民族医学   1篇
外科学   6231篇
综合类   1238篇
一般理论   29篇
预防医学   4767篇
眼科学   680篇
药学   3743篇
  2篇
中国医学   136篇
肿瘤学   2734篇
  2022年   318篇
  2021年   653篇
  2020年   437篇
  2019年   711篇
  2018年   816篇
  2017年   608篇
  2016年   737篇
  2015年   824篇
  2014年   1082篇
  2013年   1654篇
  2012年   2208篇
  2011年   2279篇
  2010年   1311篇
  2009年   1175篇
  2008年   1950篇
  2007年   2016篇
  2006年   1977篇
  2005年   1942篇
  2004年   1825篇
  2003年   1781篇
  2002年   1806篇
  2001年   1578篇
  2000年   1609篇
  1999年   1394篇
  1998年   630篇
  1997年   522篇
  1996年   441篇
  1995年   479篇
  1994年   443篇
  1993年   420篇
  1992年   1121篇
  1991年   1052篇
  1990年   1033篇
  1989年   956篇
  1988年   878篇
  1987年   904篇
  1986年   876篇
  1985年   887篇
  1984年   707篇
  1983年   605篇
  1982年   432篇
  1981年   351篇
  1980年   368篇
  1979年   578篇
  1978年   443篇
  1977年   364篇
  1976年   373篇
  1974年   379篇
  1973年   334篇
  1972年   338篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 建立蒙药绿松石的质量标准。方法 收集不同产地绿松石,共10批。观察绿松石样品和粉末的性状并进行理化鉴别;按2020年版《中国药典》(四部)通则方法测定绿松石样品中水分、浸出物含量;采用原子吸收光谱法测定绿松石样品铜元素含量。结果 绿松石为不规则、周围带有黑石的块状物,表面蓝绿色,体重,质硬脆,难砸碎,断面呈贝壳状,蜡样光泽,粉末呈灰绿色,无臭,味淡;理化鉴别结果显示,呈铜盐反应;10批次样品中水分含量为0.41%-3.94%(SD=1.37%),浸出物含量为0.21%-0.81%(SD=0.21%),铜元素含量为3.03%-4.63%(SD=0.63%)。结论 初步拟定绿松石中水分含量不得超多5.0%、浸出物含量不得低于0.10%,铜元素含量应为2.60%-4.84%,制定的标准可用于蒙药材绿松石的质量控制。  相似文献   
2.
3.
4.
5.
6.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
7.
Hepatic NADPH-cytochrome P450 oxidoreductase null (HRN?) mice exhibit normal hepatic and extrahepatic biotransformation enzyme activities when compared to wild-type (WT) mice, but express no functional hepatic cytochrome P450 activities. When incubated in vitro with [14C]-diclofenac, liver microsomes from WT mice exhibited extensive biotransformation to oxidative and glucuronide metabolites and covalent binding to proteins was also observed. In contrast, whereas glucuronide conjugates and a quinone-imine metabolite were formed when [14C]-diclofenac was incubated with HRN? mouse liver, only small quantities of P450-derived oxidative metabolites were produced in these samples and covalent binding to proteins was not observed. Livers from vehicle-treated HRN? mice exhibited enhanced lipid accumulation, bile duct proliferation, hepatocellular degeneration and necrosis and inflammatory cell infiltration, which were not present in livers from WT mice. Elevated liver-derived alanine aminotransferase, glutamate dehydrogenase and alkaline phosphatase activities were also observed in plasma from HRN? mice. When treated orally with diclofenac for 7 days, at 30 mg/kg/day, the severities of the abnormal liver histopathology and plasma liver enzyme findings in HRN? mice were reduced markedly. Oral diclofenac administration did not alter the liver histopathology or elevate plasma enzyme activities of WT mice. These findings indicate that HRN? mice are valuable for exploration of the role played by hepatic P450s in drug biotransformation, but poorly suited to investigations of drug-induced liver toxicity. Nevertheless, studies in HRN? mice could provide novel insights into the role played by inflammation in liver injury and may aid the evaluation of new strategies for its treatment.  相似文献   
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号